Physician profile
Mitchell Kirsch
NPI 1184621500
$2,193.15
in general payments reported to CMS, 2019-2025
16 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.64 · 2020: $46.98 · 2021: $312 · 2022: $351 · 2023: $329 · 2024: $661 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.81 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $454.38 | 2021-2025 | |
| Vifor Pharma, INC. | $249.23 | 2019-2023 | Korsuva, Veltassa |
| Fresenius USA Marketing, INC. | $183.28 | 2019-2024 | Velphoro, Korsuva |
| Daiichi Sankyo INC. | $175.11 | 2023-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $169.51 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $167.84 | 2021-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $159.68 | 2021-2025 | Jynarque |
| Travere Therapeutics, INC. | $150.92 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.25 | 2023-2024 | Jardiance |
| Calliditas Therapeutics US INC. | $133.25 | 2023-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $86.63 | 2021-2022 | |
| Glaxosmithkline, LLC. | $37.46 | 2021-2022 | |
| Horizon Therapeutics Plc | $29.19 | 2022 | |
| Mallinckrodt Enterprises LLC | $21.79 | 2019 | |
| Fresenius USA Manufacturing, INC. | $21.63 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.00 | 2025 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Kirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.